Global Biosimilar Development

PharmaVOICE Podcasts

Content provided by Daniel Limbach. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Daniel Limbach or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

11+ y ago

FORCE-DOWNLOAD•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on September 05, 2022 20:10 (1+ y ago). Last successful fetch was on May 12, 2019 01:16 (5y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Thought Leader: Rodeina Challand, Executive Director, Biosimilars Development, PRA International

In this episode, Rodeina Challand clears up some of the murkiness among the many terms associated with biosimilars. Then, we cover the legislation and guidelines affecting biosimilars, we discuss the possibilities of one global program, and finally talk about the future for a global standard.

For more information about PRA International, visit www.prainternational.com.

Play Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

127 episodes

#Medicine #Science #Pharma #Biotech #Clinical #Research #Drug #Daniel Limbach #Health and Well-Being #PharmaVOICE #Pharmaceutical